Goldman Sachs
NTLA icon

Goldman Sachs’s Intellia Therapeutics NTLA Stock Holding History

Goldman Sachs’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,200
Closed -$152K – 6558
2025
Q2 		$152K Hold
16,200
– – ﹤0.01% 5734
2025
Q1 		$115K Buy
+16,200
New +$164K ﹤0.01% 5759
2022
Q1 		– Sell
-15,000
Closed -$1.77M – 6806
2021
Q4 		$1.77M Buy
+15,000
New +$1.88M ﹤0.01% 4347

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs's NTLA Position: Q1 2026 in Review

Goldman Sachs increased its Intellia Therapeutics (NTLA) stake by 12% in Q1 2026, buying an estimated $2.2M and bringing the position to 1,628,241 shares worth $20.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2394.

Goldman Sachs first reported a position in NTLA in Q2 2016 and has held it in 40 quarters since. The position peaked at $161M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Goldman Sachs held 1,628,241 shares of Intellia Therapeutics worth $20.9M as of Q1 2026.
  • Goldman Sachs bought 172,622 Intellia Therapeutics shares in Q1 2026, an estimated $2.2M.
  • Intellia Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2394 holding.
  • Goldman Sachs first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 40 quarters since.
  • Goldman Sachs's Intellia Therapeutics position peaked at $161M in Q2 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.